Psilocybin in Palliative Care: What a Systematic Review Says About Safety and Efficacy

Key idea

A 2024 systematic review brings together clinical and longitudinal studies of psilocybin-assisted therapy for people with palliative care needs. Findings are cautiously optimistic: some studies report reduced psychological distress and improved well-being under clinical supervision. Safety in the short term appears manageable in structured settings. However, the evidence base is small and heterogeneous, so results should not be overgeneralized.

Editorial note: The source summary available to us does not include authors, sample sizes, outcome scales, or follow-up durations. We therefore avoid numerical claims and offer a qualitative summary only.

Why this matters for palliative care

Palliative care focuses on quality of life. Beyond pain, many patients face anxiety, low mood, fear, and loss of meaning. Standard approaches—psychotherapy, medication, and team-based support—help many but not all. Psilocybin-assisted therapy aims to address deep psychological and existential distress through one or a few supervised sessions plus structured integration therapy.

What the review covered

The review synthesized studies in which psilocybin was given with preparation, therapist support during the session, and integration afterward. It asked:

• Efficacy: Do mood, anxiety, distress, quality of life, or sense of meaning improve after supervised sessions?
• Safety: What short-term psychological reactions and physical effects occur, and what adverse events are reported?

Because the metadata are incomplete, we do not report specific measures, effect sizes, or time horizons.

What this could mean in practice

If future, larger studies confirm these signals, psilocybin-assisted therapy could become a specialist option for selected palliative care patients with significant psychological distress that has not responded to standard care. In practice this would involve:

• Careful screening and preparation, delivery by trained teams in clinical settings.
• Not a take-home regimen: typically one or a small number of in-clinic sessions with integration therapy.
• A focus on relief of suffering and quality of life, not on survival or disease control.

Signals of potential benefit

Across included studies, some participants reported less emotional distress and better subjective well-being after supervised sessions. In palliative contexts, this can mean shifts in anxiety, low mood, fears, acceptance, and sense of meaning. Most outcomes are patient-reported or clinician-rated scales—useful, but still surrogate measures rather than hard clinical endpoints.

Blinding is difficult because the experience is often unmistakable, which can increase expectations and placebo effects. Protocols vary by dose, amount of psychotherapy, setting, and who is included, adding variability to results.

Safety and clinical supervision

Within the reviewed studies, short-term safety appeared generally manageable when appropriate screening and supervision were in place. Common acute effects included transient anxiety, altered perception, and short-lived rises in blood pressure and heart rate. Many protocols exclude people at higher risk, such as those with psychotic disorders, uncontrolled cardiovascular disease, or complex medication interactions.

Safety relies on “set and setting”: thorough preparation, rapport with therapists, guidance about possible experiences, continuous support during the session, and structured post-session integration.

Legal status matters. Psilocybin is a controlled substance in many regions. Self-medication is unsafe and illegal. Any use should occur only within approved protocols and under qualified supervision.

How strong is the evidence?

Systematic reviews depend on the quality of underlying studies. Key constraints in this field include:

• Small samples and heterogeneous protocols that limit generalizability.
• Challenges with blinding, raising expectancy and placebo effects.
• Reliance on self-report and mood/quality-of-life scales rather than hard outcomes.
• Often short follow-up, leaving durability and rare delayed risks uncertain.
• Possible publication bias favoring positive findings.

In short, there is a signal of benefit, but also substantial methodological noise. Larger, standardized trials with agreed-upon outcomes and longer follow-up are needed.

Open questions

• What dosing, psychotherapeutic support, and session schedules best fit palliative care?
• Which patient subgroups are most likely to benefit with minimal risk?
• How long do benefits last, and when—if ever—are repeat sessions warranted?
• How well do results from specialized centers translate to routine care?
• How can programs ensure ethical, culturally sensitive care that respects patient values?

Practical takeaways

• Psychological distress is a core target in palliative care. Proven approaches—interdisciplinary support, psychotherapy, and symptom control—remain essential.
• Patients and caregivers interested in this topic should speak with their palliative care team. Lawful options include regulated clinical trials or approved programs.
• Clinicians should monitor developments and emphasize screening, informed consent, team-based delivery, and safety monitoring.
• Self-medication is inappropriate and risky—legally, medically, and psychologically.

Sources

• Original publication: https://pubmed.ncbi.nlm.nih.gov/41410211?fc=None&ff=20260110192237&v=2.18.0.post22+67771e2
• DOI / PubMed: 41410211

Disclaimer

This article is educational and not medical advice. Psilocybin is a controlled substance in many regions. Do not start, stop, or change any therapy without guidance from a qualified clinician and adherence to local laws.